Related Experiment Video
Updated: Jul 11, 2025

Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
Neurocognitive outcomes in pediatric hematological cancer survivors post-HSCT: A systematic review
Saniya Ansari1, Aakriti Garg1,2, Mohd Ashif Khan1
1Department of Translational & Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India.
Insights
Hematopoietic stem cell transplantation (HSCT) can lead to long-term neurocognitive impairments in pediatric cancer survivors. This review confirms adverse effects on intelligence, memory, and executive functions 5 years post-HSCT.
Area of Science:
- Neuroscience
- Oncology
- Pediatrics
Background:
- Pediatric hematological cancer survivors undergoing hematopoietic stem cell transplantation (HSCT) are at risk for long-term neurocognitive deficits.
- Understanding these long-term effects is crucial for improving survivorship care.
Conclusions:
- Evidence indicates a significant adverse impact of HSCT on neurocognitive outcomes in pediatric hematological cancer survivors long-term.
- Long-term monitoring and targeted interventions are essential to mitigate neurocognitive sequelae.
- Future research should focus on identifying risk factors and developing interventions to optimize neurocognitive functioning in this population.
Background:
Pediatric hematological cancer survivors who undergo hematopoietic stem cell transplantation (HSCT) may experience long-term neurocognitive impairments. This systematic review aims to assess the neurocognitive outcomes in pediatric hematological cancer survivors at least 5 years post-HSCT.
Methodology:
A comprehensive search was conducted in multiple databases, including PubMed, ScienceDirect, Cochrane Library, and ClinicalTrials.gov, until October 2022. Relevant studies assessing the neurocognitive affect after 5 years of HSCT were identified and included in the review. The quality of included studies was assessed using the ROBINS-I tool to evaluate the risk of bias.
Results:
A total of five studies met the inclusion criteria and were included in the review. The studies consistently demonstrated adverse effects of HSCT on neurocognitive outcomes in pediatric hematological cancer survivors after 5 years of the treatment. The most prominent impact was observed on global cognitive outcomes, including intelligence, attention, memory, and executive functioning. Specific cognitive domains, such as processing speed and academic achievement, were also significantly affected. Several studies reported a relationship between HSCT-related factors (e.g., age at transplantation, radiation therapy, graft-versus-host disease) and neurocognitive impairments.
Conclusion:
This systematic review provides evidence of the adverse impact of HSCT on neurocognitive outcomes in pediatric hematological cancer survivors at least 5 years post-transplantation. The findings highlight the importance of long-term monitoring and intervention strategies to mitigate these neurocognitive sequelae. Future research should focus on identifying risk factors and developing targeted interventions to optimize the neurocognitive functioning of this vulnerable population. Healthcare professionals involved in the care of pediatric hematological cancer survivors should be aware of these potential long-term neurocognitive effects and incorporate appropriate assessments and interventions into survivorship care plans.
More Related Videos
11:24Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
Published on: October 18, 2011
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Multipotency of Hematopoietic Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Regulation of Hematopoietic Stem Cells
Kidney Transplant III: Nursing Management